Longboard Pharmaceuticals, Inc. (LBPH)
- Previous Close
19.25 - Open
19.25 - Bid 19.64 x 400
- Ask 19.75 x 200
- Day's Range
18.86 - 20.00 - 52 Week Range
3.60 - 28.15 - Volume
179,166 - Avg. Volume
546,838 - Market Cap (intraday)
766.678M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-2.39 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.63
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
www.longboardpharma.comRecent News: LBPH
Performance Overview: LBPH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LBPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LBPH
Valuation Measures
Market Cap
766.68M
Enterprise Value
718.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
18.73
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-12.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-58.48%
Return on Equity (ttm)
-106.30%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-54.42M
Diluted EPS (ttm)
-2.39
Balance Sheet and Cash Flow
Total Cash (mrq)
48.5M
Total Debt/Equity (mrq)
1.16%
Levered Free Cash Flow (ttm)
-30.8M